Sartorius AG
Company Profile
Business description
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
Contact
Otto-Brenner-Strasse 20
GottingenNI37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
14,279
Stocks News & Analysis
stocks
Tesla: valuation is key consideration in merger talks with SpaceX
stocks
Meta earnings: Early look at Muse adoption impresses investors
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,926.60 | 20.80 | 0.23% |
| CAC 40 | 7,847.32 | 64.50 | 0.83% |
| DAX 40 | 25,410.84 | 229.19 | 0.91% |
| Dow JONES (US) | 52,321.90 | 106.74 | 0.20% |
| FTSE 100 | 10,767.33 | 76.97 | 0.72% |
| HKSE | 23,211.81 | 118.44 | 0.51% |
| NASDAQ | 26,179.93 | 224.59 | 0.87% |
| Nikkei 225 | 62,189.65 | 503.51 | -0.80% |
| NZX 50 Index | 13,733.93 | 12.91 | -0.09% |
| S&P 500 | 7,675.43 | 51.75 | 0.68% |
| S&P/ASX 200 | 8,809.90 | 14.70 | 0.17% |
| SSE Composite Index | 3,697.52 | 7.04 | 0.19% |